Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Medical Minute on Key Decisions in HIV Care: What to Do About Missed CAB Plus RPV LA Injections?

In this case example, learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Released: October 4, 2021

Information on this Educational Activity

Faculty

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.

Program Medium

This program has been made available online.

Related Content

CCO presenta a la Dra. Leticia M. Pérez Saleme explicando los factores principales a tomar en cuenta cuando se toman decisiones basadas en evidencia para optimizar el TAR en pacientes con supresión virológica en México

Leticia M. Pérez Saleme, MD Released: February 17, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 14, 2022

Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 7, 2022

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

Prof Gail Matthews, MD, PhD Released: January 25, 2022
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings